H.C. Wainwright raised the firm’s price target on Neurocrine Biosciences to $190 from $160 and keeps a Buy rating on the shares after the company announced that the top-line result from the Phase 2 study of NBI-1117568 might be announced in Q3. The firm believes 50% improvement in the PANSS scale compared to the control can be encouraging.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
- NBIX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Neurocrine launches Ingrezza capsules for dysphagia
- Neurocrine price target raised to $170 from $160 at Morgan Stanley
- Neurocrine price target raised to $173 from $169 at JPMorgan